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Abstract 
Purpose: To employ restriction inhibition assay (RIA) to screen phytochemical-rich fractions (PRFs) 
with high affinity for EcoRI and HindIII restriction sequences and correlate their interaction to an 
anticancer activity. 
Methods:  pBR322 linear plasmid DNA was used as a template to screen the sequence-selective 
inhibition of aqueous extracts of Cinnamomum zeylanicum and Picrorhiza kurroa, respectively. The 
template was further incubated with different concentrations of PRFs prior to digestion with restriction 
endonucleases HindIII and EcoRI. The Expressed Sequence Tags (ESTs) and Sequence Tag Sites 
(STS) of oncogenes were screened for the presence of EcoRI and HindIII restriction sequences to 
associate an anticancer property to PRF. 
Results: The inhibitory concentrations of Cinnamomum zeylanicum aqueous extract against HindIII and 
EcoRI endonucleases were approximately 2.5 and 5 µg/µl, respectively. No binding was observed for 
Picrorhiza kurroa at both HindIII and EcoRI restriction sites. The saponin-rich fractions of Cinnamomum 
zeylanicum showed significant (p < 0.001) inhibition as compared to control at concentrations of 
0.28±1.45 µg/µl for EcoRI and 0.11±2.68 µg/µl for HindIII endonucleases. Both EcoRI and HindIII 
restriction sites were found repeatedly in the STS and ESTs of BRCA2, the early onset oncogene. 
Conclusion: The inhibition of endonucleases by phytochemical-rich fractions provides direct evidence 
of the use of RIA for screening as well as demonstrating the binding specificity of these PRFs. The 
presence of 5’-AAGCTT-3’ & 5’-GAATTC-3’ in the ESTs of BRAC2 provides an insight into the use of 
screened components as leads in the search for novel anticancer compounds.  
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DNA is a primary target for many persuasive 
anti-tumor agents. Sequence specific binding of 
small molecules to DNA continues to attract 
considerable attention for developing effective 
therapeutic agents for control of gene expression 
[1-6]. In recent years, there has been an 
inclination towards plant derived drug discovery 
due to its lesser side effect as compared to the 
chemically synthesized counterpart. This has 
generated great deal of interest in the 
development and screening of novel natural 
products of medicinal value from plant sources. 
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In the past, techniques such as DNA foot 
printing, in vitro transcription assay, restriction 
inhibition assay, absorption spectroscopy, 
fluorescence, circular spectroscopy were used to 
study the sequence specificity of anti-tumor 
drugs [7]. In this perspective, RIA showed more 
specificity for CA than GC-rich sequence for 
adriamycin and more affinity towards GC than 
AT-rich sequence for daunomycin [8], distamycin 
A showed more specificity for AT-rich sequence 
[9-10]. Moreover, RIA was found to be capable of 
evaluating the DNA-binding affinity of pyrrolo 
[2,1-c][1,4]benzodiazepine (PBD) antitumour 
antibiotics. The assay showed much more 
sensitivity in discriminating molecules of similar 
structure such as iso-Dc-81, DC-81 and 
neothramycin [11]. An assay has been proposed 
for rapid detection of 06-alkylguanine-DNA 
alkyltransferase based on restriction 
endonuclease inhibition in many biological 
samples [12]. Recently, RIA was used to 
evaluate the rate of intercalator-driven platination 
of DNA [13] as well as binding specificity of 
mitoxantrone which showed more specificity for 
GC rich sequence [14]. 
                 
Normally all these techniques were used to study 
the sequence specificity of drug-DNA interaction 
and none as used for screening a compound 
which binds to a specific sequence of DNA in a 
quantitative manner. In this outline we set out 
experiments to screen phytochemical rich 
fractions showing specificity for 5’-GC-3’ and 5’-
AT-3’ sequences. Restriction inhibition assay 
was used to screen extract/phytochemicals 
showing affinity for EcoRI (5’-GAATTC-3’) and 
HindIII (5’-AAGCTT-3’) restriction sequences. 
Mitoxantrone and Distamycin-A were used as 
standard drugs interacting with HindIII and EcoRI 
restriction endonucleases. The current study is 
the first report to screen plant derived DNA 
binders from Cinnamomum zeylanicum bark and 
Picrorhiza kurroa rhizome extracts using RIA. 
 
The clinical significance of the work is correlated 
to the anticancer potential of the phytochemicals 
by searching for 5’-GAATTC-3’ and 5’-AAGCTT-
3’ in the STS and ESTs of BRCA 2 (oncogene). 
The STS are short tagged tracts of DNA 
sequence (200 to 500 base pair) that are 
operationally unique and have single occurrence 
in the human genome. Their location and base 
sequence are known and therefore they can be 
used as landmarks in genome mapping [15]. The 
ESTs are short sub-sequence of a transcribed 
cDNA sequence [16]. They may be used to 
identify gene transcripts, and are instrumental in 
gene discovery and gene sequence 
determination. Because these clones consist of 
DNA that is complementary to mRNA, the ESTs 
represent portions of expressed genes [17]. The 
presence of 5’-GAATTC-3’ and 5’-AAGCTT-3’ 
sequences in the coding domain of an oncogene 
provides the necessary clinical relevance of the 
protocol to screen phytochemicals which bind to 
such sequences, thereby interfering with 
transcription and protein expression of an 
oncogene. This is central for antitumorogenesis 






Cinnamomum zeylanicum bark and Picrorhiza 
kurroa rhizome were gifts from Dr AN Nauriyal, 
Director of HNB Garhwal University, India. The 
plant materials were identified as per Auyervada 
literature, by a local expert in herbal gardens, 
and confirmed by Dr. HS Dhaliwal, Professor of 
Plant Biotechnology, Department of 
Biotechnology, Indian Institute of Technology, 
Roorkee, India. 
 
Drugs and chemicals 
 
Mitoxantrone and distamycin-A were purchased 
from Sigma Aldrich Co., USA. Restriction 
Endonucleases PvuII, HindIII and EcoRI supplied 
with NEB (10 x) restriction buffer (100 mM Tris-
HCl pH 7.5, 1 mM EDTA, 100 mM magnesium 
acetate, 500 mM potassium acetate) were 
purchased from New England Biolab, UK. Stock 
solution of distamycin-A (100 μM), mitoxantrone 
(1 mM), aqueous extract of Cinnamomum 
zeylanicum and Picrorhiza kurroa (1 mg/ml) were 
prepared by dissolving each initially in minimum 
autoclaved milli-Q water before making up to 
volume with same. All solutions were stored at 4 
°C. 
 
Screening of DNA-extract binding by RIA  
 
The plasmid, pBR322, was linearized using 
PvuII. The linearized plasmid (600 µg) was 
incubated with standard drugs-distamycin-A (≈ 
10 µM), mitoxantrone (≈ 220 µM) and aqueous 
extract (10 µg to 200 µg per 20 µl of reaction 
volume) for Cinnamomum zeylanicum and (10 
µg to 1000 µg per 20 µl of reaction volume) for 
Picrorhiza kurroa for 30 min at 37 °C. The 
reaction mixtures were further incubated with 
EcoRI and HindIII respectively for 1 hr at 37 °C in 
a final volume of 20 μl. A control setup with the 
DNA along with each restriction enzyme was 
kept to analyze the results of the restriction 
inhibition assay. Each digestion was stopped by 
incubation for 20 min at 65 °C followed by 10 min 
at 4 °C.  
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Preparation of the aqueous bark extract of 
Cinnamomum zeylanicum 
 
Cinnamon bark (~500 g) was thoroughly 
powdered and kept sealed in cool, dry and dark 
conditions. Approximately 50 g was placed in a 
soxhlet apparatus and extracted in aqueous 
medium for 60 h. The extract was concentrated 
in a rotary evaporator at reduced pressure to 
give a yield of 10 % which was then lyophilized 
(ScanVac CoolSafe Freeze Drying Tm) and used 
for further studies. 
 
Preparation of phytochemical-rich fractions 
(PRFs) 
 
The aqueous extract of Cinnamomum 
zeylanicum which showed complete inhibition of 
restriction activity; was further fractionated into 
separate phytochemical enriched fractions using 
standardized protocol [18]. Four groups of 
phytochemicals were prepared as follows. (1) 
Anthraglycosides, bitter principles, flavonoids 
and arbutin (Fraction I): Powered aqueous 
extract (1 g) is moistened with about 1 ml of 10 
% ammonia solution; 5 ml methanol was added 
and the drug was then extracted for 10 min on a 
water bath. (2) Saponins (Fraction II): The 
methanol extract was prepared according to the 
method described for anthraglycosides. The 
extract was evaporated to about 1 ml, mixed 0.5 
ml water and then extracted with n-butanol 
(saturated with water). (3) Cardiac glycosides 
(Fraction III): the powdered aqueous extract (1 g) 
was mixed with 5 ml of 50 % methanol and 10 ml 
of 10 % lead (II) acetate solution and then heated 
for 10 min over a hot water bath. The filtrate was 
cooled to room temperature and then extracted 
twice with 10-ml quantity of dichloromethane. 
The combined DCM extracts were evaporated, 
the residue dissolved in DCM-methanol (1:1) and 
used for further analysis. (4) Terpenes, 
coumarins, phenol carboxylic acids and 
valepotriates (Fraction IV): Powdered aqueous 
extract (1 g) was extracted by heating under 
reflux for 15 min with 10 ml DCM. The filtrate was 
evaporated to dryness, and the residue dissolved 
in 0.5 ml toluene.  
The phytochemical rich fractions (I-IV) were 
further screened for inhibition with 5 2.5 µg/µl for 
EcoRI and HindIII endonucleases, respectively. 
The individual fractions were preincubated with 
linearized plasmid DNA (pBR322) at 37 °C for 30 
min followed by addition of restriction 
endonucleases. Each digestion was stopped by 
incubation for 20 min at 65 °C followed by 10 min 
at 4 °C. Standard drugs mitoxantrone (≈ 220 µM) 
and distamycin-A (≈ 10 µM) were used as 
positive control for HindIII and EcoRI restriction 
inhibition activity, respectively. Each of the 
samples was electrophoresed in a 1 % agarose 
gel at 100 V for 2 h.  
 
Screening for minimum inhibitory 
concentration (MIC) of active inhibitory PRFs 
 
Each of fractions I, II and III were further 
screened for minimum inhibitory concentrations 
against both EcoRI and HindIII endonucleases. 
Each fraction was preincubated with linear DNA 
at 37 °C for 30 min followed by addition of 
restriction endonucleases. The samples were 
further electrophoresed in a 1 % agarose gel at 
100 V for 2 hr. 
 
Screening for the presence of EcoRI and 
HindIII recognition sequence in mRNA, STS 
and ESTs of oncogene   
 
The mRNA library of oncogene was screened for 
the presence of 5’-GAATTC-3’ and 5’-AAGCTT-
3’ from Sanger.ac.uk/genetics/CGP/census. The 
oncogene with maximum hits of EcoRI and 
HindIII restriction sites were selected and 
analyzed further for the presence of 5’-GAATTC-
3’ and 5’-AAGCTT-3’ in the STS and ESTs of the 
oncogene.  
 
Agarose gel electrophoresis 
 
The digestion mixture (20 μl) was mized with 5 μl 
of 6 x DNA loading dye (0.25 % bromophenol 
blue and 30 % glycerol) and loaded on 1 % 
horizontal agarose gel; which was run in Tris-
acetate EDTA buffer (40 mM Tris base, pH 8.0, 
18 mM glacial acetic acid and 1 mM EDTA) at 
100 V for 2 h. The gel was exposed to 220 nm 
near UV region spectrum and then the DNA 
bands were visualized and analyzed for drug-
DNA interaction studies. For quantitative 
determinations, the integrated intensity of the 
ethidium bromide flouresence of the bands 
(relaxed form) were acquired and measured 
using DIANA and TINA programs (image 
analysis and acquisition system operating 
simultaneously with a Fuji camera connected to 





Data are presented as mean ± SEM (standard 
error of mean) of three independent experiments. 
Statistical significance was evaluated by two 
tailed unpaired t-test using Origin software 
(Origin Lab Corporation, USA), version 6.1. P < 
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DNA-extract binding  
 
DNA-extract binding was examined by 
measuring the inhibition of restriction 
endonucleases. Aqueous extract of 
Cinnamomum zeylanicum with concentrations 
ranging from 0.5 µg to 50 µg per µl and 0.5 µg to 
10 µg per µl inhibited EcoRI and HindIII 
endonucleases, respectively, in a concentration-
dependent manner. The MIC of the extract of 
Cinnamomum zeylanicum was approximately 
2.500 ± 5.77 for HindIII and 5.006 ± 9.28 µg/µl 
for EcoRI and was statistically significant (p < 
0.001) as compared to the positive control. While 
aqueous extract of Picrorhiza kurroa showed no 
binding with concentrations ranging from 0.5 to 
50 µg per µl for both EcoRI and HindIII restriction 
sequences. Mitoxantrone at 113.828 ± 0.4857 
ng/µl or ≈ 220 µM and distamycin-A at 5.1797 ± 
0.0288 ng/µl or ≈ 10 µM were bound selectively 
to EcoRI and HindIII restriction sites, 
respectively, and were used as positive control 




Figure 1: Agarose gel (1%) showing restriction 
inhibition assay of aqueous extract of Cinnamomum 
zeylanicum and Picrorhiza kurroa with HindIII 
restriction endonucleases. Lane 1: Linear plasmid 
(pBR322) + HindIII; Lane 2: Positive control-linear 
plasmid (pBR322) + HindIII + Mitoxantrone (220 µM); 
Lane 3-6: aqueous extract of Cinnamomum 
zeylanicum-linear plasmid complex was digested by 
HindIII with the extract concentration of 0.5, 2.5, 5 and 
10 µg/µl, respectively; Lane 7: Linear plasmid 
(pBR322) + HindIII; Lane 8: Positive control-Linear 
plasmid (pBR322) + HindIII + Mitoxantrone (200 µM); 
Lane 9-13: aqueous extract of Picrorhiza kurroa-linear 
plasmid complex was digested by HindIII with the 
extract concentrations of 0.5, 2.5, 5, 10 and 50 µg/µl, 
respectively. 
 
RIA of PRF of Cinnamomum zeylanicum 
extract 
 
The binding of fractions (I-IV) to both EcoRI and 
HindIII restriction sites were examined by 
inhibition of restriction endonucleases EcoRI and 
HindIII. Each of the Fractions (I, II and III) of 
Cinnamomum zeylanicum aqueous extract 
showed complete inhibition at approximately 
2.500 ± 2.89 and 5.006 ± 4.41 µg/µl for HindIII 
and EcoRI endonucleases, respectively. Fraction 
IV (terpenes, coumarins, phenol carboxylic acids, 





Figure 2: Agarose gel (1 %) showing restriction 
inhibition assay of aqueous extract of Cinnamomum 
zeylanicum and Picrorhiza kurroa with EcoRI 
restriction endonuclease. Lane 1: linear plasmid 
(pBR322) + EcoRI; Lane 2: Positive control-linear 
plasmid (pBR322) + EcoRI + Distamycin-A (10 µM); 
Lane 3-6: Aqueous extract of Picrorhiza kurroa-linear 
plasmid complex digested by HindIII with the extract 
concentration of 2.5, 5, 10 and 50 µg/µl, respectively. 
Lane 7: Linear plasmid (pBR322) + EcoRI; Lane 8: 
Positive control-Linear plasmid (pBR322) + HindIII + 
Distamycin-A (10 µM); Lane 9-13: aqueous extract of 
Cinnamomum zeylanicum-linear plasmid complex 
digested by EcoRI with the extract concentrations of 




Figure 3: Agarose gel (1 %) showing restriction 
inhibition assay of fractions I to IV of Cinnamomum 
zeylanicum aqueous extract with both EcoRI and 
HindIII restriction endonucleases. Lane 1: Linear 
plasmid (pBR322) + EcoRI; Lane 2: Positive control-
Linear plasmid (pBR322) + EcoRI + Distamycin-A (10 
µM); Lanes 3-6: Fractions I, II, III and IV of 
Cinnamomum zeylanicum and linear plasmid complex 
digested by EcoRI with approximately 5 µg/µl. Lane 7: 
Linear plasmid (pBR322) + HindIII; Lane 8: positive 
control-Linear plasmid (pBR322) + HindIII + 
Mitoxantrone (220 µM); Lane 9-12: Fractions I, II, III 
and IV of Cinnamomum zeylanicum and linear plasmid 
complex digested with HindIII by each fraction with 
approximately 2.5 µg/µl.  
 
MIC of active inhibitory PRF (I to III) of 
Cinnamomum zeylanicum 
 
The affinity of fractions I to III for EcoRI and 
HindIII restriction sequences were examined. 
Fraction I at concentrations of 2.28 ± 4.41 and 
0.75 ± 4.28 µg/µl, fraction II at 0.11 ± 2.68 and 
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Table 1: A summary of quantitative and qualitative binding data for fractions I, II, III and IV of Cinnamomum 
zeylanicum extract  
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principles, Flavonoids and 






113.828 ± 0.4857 
ng/µl or ≈ 220 µM 
(HindIII), 5.1797 ± 
0.0288 ng/µl or ≈ 
10 µM (EcoRI ) 
2.28 ± 4.41  µg/µl¥ 
(EcoRI ), 0.75 ± 




























Saponins (Fraction II) 4.363 kb 0.28 ± 1.45 µg/µl 
(EcoRI ) ¥, 0.11 ± 










 (Fraction III) 
4.363 kb 0.748 ± 1.1547 











Phenol carboxylic acids, 
Valepotriates (Fraction IV) 
4.363 kb No binding 
observed 





#Concentration of different phytochemical rich fractions required to inhibit restriction endonuclease cleavage by 100%. 
*Sequence selective binding of different phytochemical chemical rich fractions to the linear pBR322 plasmid DNA. 
Data are the mean ± S.E.M of three independent experiment performed in triplicates;  ¥statistically significantly different 
compared to control  (p < 0.001). 
 
Table 2: Occurrence of both HindIII (5’-AAGCTT-3’) and EcoRI (5’-GAATTC-3’) restriction sequences in the STS 
and ESTs of Breast cancer 2 early Onset Gene (BRCA 2). 
 
NAME BRCA 2 
GENE ID 675 
Occurrence of EcoRI (5’-GAATTC-3’) in 
mRNA 
5 
Occurrence of HindIII (5’-AAGCTT-3’) in 
mRNA 
4 
Occurrence of EcoRI (5’-GAATTC-3’) in STS 
of BRCA 2 
UniSTS-272209 (1) 
Occurrence of HindIII (5’-AAGCTT-3’) in 
STS of BRCA 2 
UniSTS-272803 (1); UniSTS-272880 (1); UniSTS-505289 (1) 
Occurrence of EcoRI (5’-GAATTC-3’) in 
ESTs of BRCA 
dbEST Id: 1457605; dbEST Id: 27576196; dbEST Id: 37888790; 
dbEST Id:7737797; 
Occurrence of HindIII (5’-AAGCTT-3’) in 
ESTs of BRCA 
dbEST Id: 6572441: dbEST Id: 37888790;  dbEST Id: 22570003   
 
0.28 ± 1.45 µg/µl and fraction III at 0.75 ± 1.15 
and 2.67 ± 1.76 µg/µl inhibited HindIII and EcoRI, 
respectively, in a concentration-dependent 
manner (Table 1). The MIC of fraction II for both 
HindIII and EcoRI was comparatively lesser than 
that of the other two fractions I and III. The MIC 
obtained for each fraction was significantly 
different from that of control (p < 0.001). 
 
EcoRI and HindIII recognition sequence in 
mRNA, STS and ESTs of the oncogenes   
The library of oncogenes was screened for the 
presence of 5’-GAATTC-3’ and 5’-AAGCTT-3’ 
sequence, respectively. The oncogene Breast 
cancer 2, early onset mRNA (BRCA2) with 
maximum hits of EcoRI and HindIII restriction 
sites was selected (Table 1). The occurrence of 
5’-GAATTC-3’ and 5’-AAGCTT-3’ in each STS 
and ESTs of the selected oncogene are shown 




Reagents that bind sequence selectively to 
double stranded DNA are of considerable 
interest in medicinal chemistry and molecular 
biology as they may possibly provide the tools for 
sequence specific modification of DNA and for 
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gene targeted drugs [1-6]. Even though DNA foot 
printing, in vitro transcription assay, absorption 
spectroscopy, fluorescence, circular dichromism 
spectroscopy have emerged as powerful tools for 
analyzing drug/DNA association phenomena [4], 
they have been unsuccessful in screening 
component binding specifically to nucleic acid 
sequences.  
 
In this regard, restriction inhibition assay (RIA) 
yielded results similar to those obtained by DNA-
binding affinity assays, namely, thermal 
denaturation and ethidium bromide displacement 
assays. Moreover, it was much more sensitive in 
discerning between molecules of comparable 
structures [11]. This assay was also used to 
determine the rates of intercalator-driven 
platination of DNA by four non-cross-linking 
platinum-acridine agents represented by the 
formula [Pt(am(2))LCl](NO(3))(2), where am is a 
diamine nonleaving group and L is an acridine 
derived from the intercalator 1-[2-(acridin-9-
ylamino)ethyl]-1,3-dimethylthiourea (ACRAMTU) 
[12]. Restriction inhibition assay has also been 
used to measure O6-alkylguanine-DNA 
alkyltransferase (AGT) levels in large numbers of 
small biological samples [13]. In this context, this 
assay can be performed in basic laboratories and 
would allow rapid processing of many samples 
concurrently, which could prove useful in clinical 
and epidemiological studies. Based on this 
perspective, the potential of RIA to screen drugs 
or phytochemical binding specifically to DNA is 
exceptional. The principle of RIA assay is based 
upon the ability of different phytochemical rich 
fractions to inhibit the cleavage activity of HindIII 
and EcoRI restriction endonucleases [14]. In the 
initial screening, aqueous extract of 
Cinnamomum zeylanicum showed inhibition of 
both HindIII and EcoRI endonucleases in a 
concentration dependent manner. The minimum 
inhibitory concentration (MIC) of the aqueous 
extract of Cinnamomum zeylanicum was 2.500 ± 
5.77 for HindIII and 5.006 ± 9.28 µg/µl for EcoRI 
but no binding was observed for aqueous extract 
of Picrorhiza kurroa.  
 
The assay showed sequence specificity and 
affinity of the different fractions towards AAGCTT 
and GAATTC (reading in the 5’-3’ direction). On 
the whole, the phytochemical rich fractions 
(PRFs) showed more affinity for HindIII restriction 
sequence than for EcoRI restriction sequence. 
The above observations support the hypothesis 
of using RIA to screen both qualitatively and 
quantitatively sequence specific DNA binding 
components from herbal plants. 
 
The clinical significance of this novel screening 
protocol was evaluated by screening for the 
presence of 5’-GAATTC-3’and 5’-AAGCTT-3’ in 
the cDNA or mRNA of oncogenes from 
oncogene database of Sangers Laboratory, 
United Kingdom. The oncogenes BRCA 2 
showed maximum repeats of 5’-GAATTC-3’and 
5’-AAGCTT-3’, respectively. To be more specific 
we analyzed the STS and ESTs, for the 
presence of 5’-GAATTC-3’and 5’-AAGCTT-3, 
respectively in the BRCA 2 early onset 
oncogene. The 5’-GAATTC-3’and 5’-AAGCTT-3 
sequences were observed in the STS and ESTs 
of BRCA 2 cDNA/mRNA breast cancer 2, early 
onset oncogene. The STS are DNA sequences 
which are unique for a gene which may or may 
not be the coding region of the same [15,16]. On 
the other hand ESTs are unique coding 
sequences of any gene [17]. Therefore, the 
presence of drug specific sequence in the ESTs 
and STS may provide a unique target for cancer 
therapy. Consequently, targeting ESTs can 
directly present a site-directed attack to inhibit 
the expression of the oncogene by the screened 




This study clearly shows that RIA can be used to 
screen compounds which can bind to specific 
sequences 5’-GAATTC-3’and 5’-AAGCTT-3 in 
the STS and ESTs of any oncogene. Therefore, 
the potential application of the findings of this 
study indicates the immense potential of the 
approach in screening novel plant derived 
inhibitor which binds to certain sets of 
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